Aromatase inhibitors boost breast cancer survival rates

Better survival outcomes with aromatase inhibitors support their use over tamoxifen as initial therapy for postmenopausal women with early breast cancer, a major review suggests.

Analysis of data from 30,000 women treated for early breast cancer found that compared with tamoxifen, taking aromatase inhibitors for five years further reduced the likelihood of the cancer recurring by 30%, and the risk of dying from breast cancer by about 15% throughout the decade after treatment was commenced.

The review by the Early Breast Cancer Trialists' Collaborative Group, published in the